Formulation and Evaluation of Nanoparticles Containing Antiviral Protease Inhibitor

College of Pharmacy, Dr. A. P. J. Abdul Kalam University, Indore, Madhya Pradesh, India

*Corresponding Author: Dr. Sourabh Jain, College of Pharmacy, Dr. A. P. J. Abdul Kalam University, Indore, Madhya Pradesh, India; Tel: +91 94250 42457 Email: [email protected]

Received Date: 02 January 2023

Published Date: 03 February 2023

ABSTRACT

Atazanavir (ATV) is a HIV protease inhibitor. Due to its intense lipophilicity, the oral delivery of ATV encounters several problems such as poor aqueous solubility, pH-dependent dissolution, rapid first-pass metabolism in liver by CYP3A5, which result in low bioavailability. To overcome aforementioned limitations, ATV-loaded chitosin nanoparticles (ATV NPs) were prepared to enhance oral bioavailability. ATV NPs were prepared by nano precipitation method. In the present study Chitosan nanoparticles containing Atazanavir was prepared. The effect of increase in Chitosan concentration on various parameters like particle size, zeta potential and in vitro release profile were studied. The Atazanavir nanoparticles were formulated and evaluated for its in vitro drug release profile. Based on the drug content, entrapment efficiency, particle size, zeta potential and in vitro drug release profile of Atazanavir nanoparticles formulations formulation AZNP3 was selected as the best formulation in which the particle size was 227.9nm. The in vitro % drug release of AZNP3 formulation was 99.85% and it was found to be suitable formulation to manage the condition of HIV. Hence it can be concluded that the newly formulated controlled release nanoparticulate drug delivery systems of Atazanavir may be ideal and effective in the management of HIV by allowing the drug to release continuously for 24 hrs. The studies, therefore, indicate the successful formulation development of NPs with distinctly improved bioavailability potential and can be used as drug carrier for sustained or prolonged drug release.

Keywords: Atazanavir, Nanoparticles, Chitosan, In-vitro